Nektar tried to clarify data failure
Nektar tried to clarify data failure June 04, 2018 Source: Sina Pharmaceutical Recently, Bristol-Myers Squibb (BMS) and Nektar announced global strategic development and commercial cooperation for its leading immuno-oncology project NKTR-214. However, just announced the cooperation, the NKTR-214 test has made a major mistake. At the annual meeting of the American Society of Clinical Oncology (ASCO) this weekend, Nektar researchers explained why the latest data from this small study should not cause panic. In this cooperation, the two companies will jointly promote NKTR-214 on a global scale. BMS will lead the promotion of NKTR-214 and its drug portfolio, and Nektar will be responsible for promoting such products in the US, major EU markets and Japan. Nektar will lead the global promotion of NKTR-214 in combination with its pharmaceutical or third-party drugs. Under the terms of the agreement, BMS will pay an advance payment of $1.85 billion and Nektar will be eligible for an additional $1.78 billion in milestone payments. In this trial, the researchers performed a two-stage trial procedure to recruit a group of cancer patients to test the efficacy of different cancer types. After the first phase, the patients will enter the next phase of the trial with a new batch of subjects. Nektar Chief Medical Officer Mary Tagliaferri said that the reason for this is to respond to the consensus reached when communicating with regulators, that is, the strategy of jumping directly into later research. Nektar hopes that the trial will enter Phase III as soon as possible. In the melanoma trial, the researchers found that 11 of the 13 patients treated with Opdivo and NKTR-214 were well controlled in the first round. However, when 15 patients were added, the number of patients responding to the drug combination increased by only 3 patients. A 20% response rate is clearly a very unsuccessful result. In the kidney tumor test, the overall response rate in the first phase was 64%, and then the overall response rate in the second phase plummeted to 46%. The poor data performance could not help but cause widespread concern among investors. Because this key data of efficacy will seriously affect the success of long-term sales of this cancer drug. NKTR-214 is a research and development immunostimulation therapy of the company. It has a therapeutic effect similar to that of antibodies, which can stimulate the growth of T cells and thus achieve the killing effect on tumors. Moreover, it is important to increase the number of tumor infiltrating lymphocytes (TILs) in the body, as many patients are unable to benefit from the currently approved immunological checkpoint inhibitors due to the lack of sufficient TILs in the body. Opdivo (Nivolumab) is a PD-1 immunological checkpoint inhibitor that has been approved for the treatment of a variety of cancers including melanoma, non-small cell lung cancer, liver cancer, bladder cancer, and renal cell carcinoma. Opdivo and NKTR-214 have two different and complementary mechanisms of action, so the combination of the two is expected to improve the body's immune system's ability to fight cancer. Under this collaboration, the two companies will jointly develop and promote the combined use of NKTR-214 and BMS Opdivo and Opdivo+Yervoy in more than 20 indications for 9 tumor types, as well as with other companies or third parties. A combination of anticancer drugs. In January 2018, Nektar attended the 36th JP Morgan Medical Conference in San Francisco, USA, and announced a number of promising drug developments. According to S&P Global Market Intelligence, the company's share price soared by 40% at an alarming rate in a month. Whether the reasons for this explanation can be recognized by investors, Nektar's future share price performance will give an answer. (Sina Pharmaceutical Compilation / Fan Dongdong) Article reference source: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an ASCO stampede Plant extracts refer to a class of substances derived from plants that have one or more biological functions. Can be separated by physical and chemical extraction of one or more effective components formed by natural products. plant extract,buy plant extract,wholesale plant extract,plant extract benefits,plant extract for sale Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropics.com
There are many kinds of plant extracts. At present, natural plant extracts mainly include essential oils, saponins, alkaloids, polysaccharides, polyphenols, flavonoids and so on. According to the biological activity, it can be divided into antioxidants: grape seed extract, green tea extract, pine bark extract, etc. Immune modulators: ginseng extract, gynostemma pentaphyllum extract, Ganoderma lucidum extract, etc. Improve cardiovascular function: ginkgo biloba extract, lotus seed heart extract, rhodiola extract, etc. Sedative: valerian extract, hop extract and so on.
According to their own characteristics in the market application of plant extracts can be roughly divided into six categories: coloring, seasoning, medicinal, health, dietary supplements and feed additives. Natural plant pigments refer to pigment components in roots, stems, leaves, flowers, fruits and bark of plants, such as turmeric, sappanwood, indigo, safflower, black bean and green walnut peel. Natural plant pigments are widely used in food, textiles, cosmetics, medicine, leather industry, printing and dyeing and other industries.
Plant extracts are rich in ingredients that can effectively stimulate the senses, such as sweeteners and volatile substances. Natural sweeteners, such as stevia glycoside and grosvenin, are popular new sweeteners. They are not only sweet, but also ideal substitutes for sucrose. Essential oils are concentrated volatile substances that are commonly used in the preparation of fragrances and are widely recognized in plant extracts.
Contained in the plant extracts of saponins, alkaloids, polyphenols, flavonoids and other ingredients are widely study has many biological activities, such as antioxidant, antibacterial, anti-inflammatory, improve animal production performance, antivirus, enhance immunity, etc., for human and animal health has the effect of nots allow to ignore, and the development of its pharmacology and health care function has become the main trend of plant extracts.In addition, as a dietary supplement, it is one of the main applications of various plant extracts. Such as oligosaccharides (oligosaccharides, oligosaccharides, oligosaccharides, galactose, etc.) dietary fiber, soybean protein, dietary fiber, wheat albumin, L-arabinose, sugar alcohol (xylitol, malt heavy sugar alcohol, sorbitol, etc.) and other natural plant food additives have been widely used in the food health care market. Many plant functional ingredients with anti-inflammatory, antioxidant and bacteriostatic properties are also commonly used as substitute anti-bacterial products. The application of green feed additives in livestock and poultry production has been vigorously developed, such as green tea polyphenols extract, pine bark procyanidins extract and polyanthocyanidins extract.
Due to the changes in lifestyle, working mode and consumption mode, more consumers are pursuing the life concept of "big health". The so-called "big health" refers to a concept of whole-process, comprehensive and total factor care for people's life around the basic necessities of life, life, old age, illness and death. It not only pursues individual physical and physical health, but also pursues mental, spiritual, social, environmental and family health. In the era of "great health", natural plant-based health products are the core and the key material basis.
With increasing attention to the food and drug safety, from natural plant in the development and utilization of the active ingredient is becoming more and more attention, a large number of food safety, have certain curative effect function of plant extracts have been used as raw materials in a variety of ways into functional food nutrition and health food has entered people's lives, and will play a more and more important role.
And more and more new research new discovery, predicts that the plant extract industry chain will have more members to join, there will be more business opportunities. The future domestic plant extract market will stride forward gradually to mature period!
Shaanxi Yingyuan Xingchuang Biotechnology Co., Ltd. is committed to plant extracts, advanced pharmaceutical intermediates, featured apis, and other customized research and development services; Relying on its GMP production base, it has set up a RESEARCH and development center and GMP pilot workshop to accelerate the commercialization process of production and research. The company has accumulated a number of invention patents, and has been declared by more than ten regulatory bodies such as China, FDA of the United States, EDQM of the European Union, India, Japan, South Korea and Australia. Please feel free to contact us.